演題詳細

ポスター / Poster

ポスター 47 (Poster 47) :細胞療法

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F エメラルドABCD)
座長・司会
三浦 康生 (Yasuo Miura):1
1:京都大学医学部附属病院 輸血細胞治療部
 
前へ戻る

WT-1 pulsed allogeneic DC therapy induced long-term remission in a patient with refractory ALL

演題番号 : PS-1-357

齋藤 章治 (Shoji Saito):1,2、田中 美幸 (Miyuki Tanaka):2、柳沢 龍 (Ryu Yanagisawa):1,2、坂下 一夫 (Kazuo Sakashita):2、吉川 健太郎 (Kentaro Yoshikawa):1,2、倉田 敬 (Takashi Kurata):2、平林 耕一 (Koichi Hirabayashi):2、中沢 洋三 (Yozo Nakazawa):2、小池 健一 (Kenichi Koike):2、下平 滋隆 (Shigetaka Shimodaira):1

1:Cell Processing Center, Shinshu University Hospital, Matsumoto, Japan、2:Department of Pediatrics, Shinshu University, Matsumoto, Japan、3:Department of Hematology and Oncology, Nagano Children's Hospital, Azumino, Japan

 

(Introduction) Prognosis remains dismal in hematological malignancy patients who relapsed after stem cell transplantation. Immunotherapy may be promising strategy to overcome the drug resistant leukemic clones.
(Case report) A 15-year-old girl was referred to our department because of third relapse after second hematopoietic stem cell transplantation (HSCT) from her HLA matched mother in November 2008. Combination of chemotherapy and HSCT could not provide sustained remission longer than 11 months. Third HSCT in December 2008 from one locus HLA mismatched sibling achieved complete hematological remission. HLA-A*24:02-restricted WT1 peptide pulsed dendritic cell (DC) vaccines were generated from the third donor. After third HSCT, 14 sessions of DC vaccine had been carried out from June 2010 until Feburary 2011. She never developed GVHD during DC therapy, and the only adverse effect was local skin erythema at the vaccine injection sites. Disease-free survival continued until fourth relapse in August 2012. WT1 antigen specific cytotoxic cells increased from 0.01% to 0.57% of CD8 positive cells after DC vaccination. At the fourth relapse, WT1 antigen specific CTLs remained 5.49% of CD8-positive cells in the peripheral blood.
(Conclusion) WT1-pulsed allogeneic DC therapy was well tolerated and safe without any GVHD. This strategy might be effective to maintain long-term remission in the patients with refractory relapsed leukemia.

前へ戻る